logo
  

Gilead's Twice-yearly HIV Drug Sunlenca Gets European Commission Approval

Gilead Sciences Inc. (GILD) said on Monday that the European Commission has approved Sunlenca injection and tablets for the treatment of HIV infection, in combination with other antiretrovirals, in adults with multi-drug resistant HIV.

Sunlenca, known generically as Lenacapavir, is a first-in-class capsid inhibitor.

The European Commission approval applies to all 27 member states of the European Union, as well as Norway, Iceland and Liechtenstein. The drug will now be the only twice-yearly treatment for people who struggle with multi-drug resistant HIV.

In the U.S., Lenacapavir, proposed for the treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection, is under FDA review, with a decision due on December 27, 2022.

This is Lenacapavir's second go-around with the FDA. The U.S. regulatory agency had refused to approve Lenacapavir in March of this year, citing issues related to compatibility of vials and Lenacapavir solution.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google, owned by Alphabet Inc., plans to merge its teams working on Maps products and the mapping service Waze with effect from December 9, reports said. The decision to consolidate processes comes as the search giant is facing pressure to streamline operations and cut costs. The restructuring is expected to reduce overlapping work across the Waze and Maps products. The Pentagon announced that up to $9 billion worth of cloud-computing contracts were awarded to Google, Oracle, Amazon, and Microsoft. In a statement, the U.S. Department of Defense said, "The purpose of this contract is to provide the Department of Defense with enterprise-wide, globally available cloud services across all security domains and classification levels..." Juul Labs, an e-cigarette maker, said it has reached settlements with more than 5,000 vaping lawsuits in the United States. The cases were related to personal injury, consumer class action, government entity, and Native American tribes. In a statement, the company said it cannot disclose the settlement amount at this time as part of the settlement and court process.
Follow RTT